Xcout Intel
ScandiBio
ScandiBio Therapeutics is a clinical-stage biotechnology company headquartered in Stockholm, Sweden, founded to develop pharmaceutical drugs targeting mitochondrial dysfunction.
Subscribe to see ScandiBio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
ScandiBio at a glance
ScandiBio is a biotech company headquartered in Sweden. Xcout tracks 9 named people at ScandiBio, including Magnus Nylén (Chief Executive Officer (CEO)).
ScandiBio leadership
- Magnus NylénChief Executive Officer (CEO)
- Dr Marianne HanssonChief Financial Officer (CFO)
- Dr Adil MardinoğluChief Scientific Officer (CSO)
- Dr Özlem AltayChief Medical Officer (CMO)
- Dr Mathias UhlénSenior Professor of Microbiology Co-founder, Chairman of the Board
- Dr Adil MardinoğluProfessor of Systems Biology Co-founder
3 more named people on record for ScandiBio, with roles, board committees and tenure — see the full roster →
ScandiBio competitors
A few of ScandiBio's closest competitors — see the full list of competitors and alternatives →
Abliva is a company headquartered in Lund, Sweden, focused on delivering mitochondrial health. It leverages in-house R&D capabilities to create a portfolio of projects with various mechanisms of action.
Atrogi is a clinical-stage biotechnology company headquartered in Stockholm, Sweden, pioneering the development of novel treatments for metabolic disorders.
MitoRx Therapeutics is a platform biotechnology company headquartered in Oxford, England, developing novel mitochondrial-targeted therapeutics for life sciences.
Pretzel Therapeutics is a biotechnology company headquartered in Boston, Massachusetts, advancing a new class of medicines that target cellular energetics and mitochondrial function.
Cellvie AG is a biotechnology company based in Zurich, Switzerland, pioneering Therapeutic Mitochondria Transplantation to target cellular energy metabolism.
Paean Holdings, Inc. (operating as PAEAN Biotechnology) develops mitochondria-based therapeutics designed to treat rare diseases, inflammatory conditions, cancer, and central nervous system disorders. The company utilizes proprietary platforms including mitochondrial transplantation, modified mitochondria for targeted delivery, and mitochondria-augmented cell therapy to address critical medical needs and overcome cellular metabolic limitations.
Get ScandiBio's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on ScandiBio in Xcout Intel
- 9 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access